- Home
- IZEA vs MCRB Comparison
IZEA vs MCRB Comparison
Compare IZEA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IZEA | MCRB |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | 75 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 41.2M |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IZEA | MCRB |
|---|---|---|
| Price | $2.31 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 45.1K | ★ 70.9K |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,099,695.00 | $789,000.00 |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $20.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $2.02 |
| 52 Week High | $5.59 | $29.98 |
Technical Indicators
Market Signals| Indicator | IZEA | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 19.80 |
| Support Level | $2.13 | N/A |
| Resistance Level | $2.70 | $9.53 |
| Average True Range (ATR) | 0.12 | 0.21 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 40.36 | 13.73 |
Price Performance
Historical ComparisonAbout IZEA IZEA Worldwide Inc.
IZEA Worldwide Inc is a full-service creator economy agency powered by proprietary ZED technology, with a mission to make Creator Economy solutions for marketers. It does this by lighting up the Creator Economy with IZEA's strategies, campaigns, and solutions that build brands and drive demand. Since launching the industry's first-ever influencer marketing platform in 2006, IZEA has facilitated nearly 4 million collaborations between brands and creators.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.